Congress trades
Nektar Therapeutics (NKTR)
Free on iOS and Android.
About Nektar Therapeutics
from the company's filings and listing, as of Oct 25, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Howard W. Robin
- Employees
- 63
- Listed since
- May 3, 1994
- Market value
- $1.1B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$4.75
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 13, 2026 | -$1.23 | -$1.97 | $10.1M | $10.4M | EPS beat, GAAPRevenue miss |
| Q1 FY2026reported May 7, 2026 | -$1.82 | -$1.58 | $10.9M | $10.7M | EPS miss, GAAPRevenue beat |
| Q4 FY2025reported Mar 12, 2026 | -$1.78 | -$2.47 | $21.8M | $10.2M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$1.85 | -$2.85 | $11.8M | $10.1M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 7, 2025 | -$2.95 | -$3.03 | $11.2M | $9.5M | EPS beat, GAAPRevenue beat |
| Q1 FY2025reported May 8, 2025 | -$3.60 | -$2.56 | $10.5M | $15.4M | EPS missRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 24, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Howard W. RobinPresident and Chief Executive Officer | $1.1M | $942K | $4.2M | $6.3M |
| Jonathan Zalevsky, Ph.D.Chief Research and Development Officer | $718K | $272K | $1.3M | $2.3M |
| Sandra GardinerInterim Chief Financial Officer | $0 | $0 | $686K | $686K |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| FMR LLC | $353.8M | 5,067,920 | +17.8% | 15.33% |
| Two Seas Capital LP | $215.9M | 3,092,234 | +57.8% | 9.35% |
| BlackRock, Inc. | $205.4M | 2,941,851 | +324.7% | 8.90% |
| BVF IncBVF Partners | $166.9M | 2,391,075 | -6.6% | 7.23% |
| Vanguard Capital Management LLC | $104.5M | 1,496,849 | +25.0% | 4.53% |
| Two Sigma Investments, LP | $83.9M | 1,202,004 | +29.1% | 3.64% |
| Vestal Point Capital, LP | $69.8M | 1,000,000 | +250.9% | 3.03% |
| Morgan Stanley | $65.4M | 936,560 | +42.0% | 2.83% |
| State Street Corp | $63.5M | 909,679 | +271.7% | 2.75% |
| Geode Capital Management, LLC | $61.5M | 881,306 | +154.1% | 2.67% |
| Prosight Management, LP | $56.5M | 810,000 | +10.2% | 2.45% |
| Armistice Capital, LLC | $50.5M | 724,000 | +25.3% | 2.19% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Tracked fund managers holding NKTR
4 managers| Manager | Value | Shares | Share of book |
|---|---|---|---|
| BVF Partners | $166.9M | 2,391,075 | 4.3% |
| Vestal Point Capital | $69.8M | 1,000,000 | 1.6% |
| Armistice Capital | $50.5M | 724,000 | 0.6% |
| OrbiMed | $32.5M | 465,346 | 0.6% |
4 of the 97 fund managers we track list NKTR shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in NKTR
7 disclosures of 7 on record · median 37d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -88.3%S&P 500 +153.4% · -241.7 pts vs S&P 500 | Sep 16, 2019 | Oct 16, 2019 | 30d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -92.7%S&P 500 +177.1% · -269.8 pts vs S&P 500 | Jun 3, 2019 | Jul 11, 2019 | 38d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -92.6%After the saleS&P 500 +168.8% · -261.5 pts vs S&P 500 | Jun 5, 2019 | Jul 11, 2019 | 36d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -95.9%S&P 500 +174.1% · -269.9 pts vs S&P 500 | Jun 6, 2018 | Oct 2, 2018 | 118d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -95.6%After the saleS&P 500 +176.0% · -271.5 pts vs S&P 500 | Jun 21, 2018 | Oct 2, 2018 | 103d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -96.8%After the saleS&P 500 +185.0% · -281.8 pts vs S&P 500 | May 8, 2018 | Jun 8, 2018 | 31d |
| Ro Khanna | Stock | Not captured | $1,001 - $15,000 | -97.5%S&P 500 +191.7% · -289.2 pts vs S&P 500 | Apr 3, 2018 | May 10, 2018 | 37d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in NKTR, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded NKTR?
Ro Khanna and Josh Gottheimer disclosed NKTR transactions in the filings shown here.
How quickly are NKTR trades disclosed?
Congressional disclosures took a median of 37 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.